<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font27 { font-size : 27; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">CVS </span>
   <span class="font27">vomiting </span>
   <span class="font20">treatment </span>
   <span class="font19">patients </span>
   <span class="font18">cyclic </span>
   <span class="font17">syndrome </span>
   <span class="font17">adults </span>
   <span class="font16">use </span>
   <span class="font16">prophylactic </span>
   <span class="font16">symptoms </span>
   <span class="font15">CVS. </span>
   <span class="font15">Cyclic </span>
   <span class="font15">nausea </span>
   <span class="font15">recommend </span>
   <span class="font15">clinical </span>
   <span class="font15">migraine </span>
   <span class="font15">used </span>
   <span class="font15">committee </span>
   <span class="font14">aprepitant </span>
   <span class="font14">episodes </span>
   <span class="font14">patient </span>
   <span class="font14">{border-style </span>
   <span class="font13">sumatriptan </span>
   <span class="font13">based </span>
   <span class="font13">diagnosis </span>
   <span class="font13">effects </span>
   <span class="font13">efficacy </span>
   <span class="font13">management </span>
   <span class="font13">px;} </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">acute </span>
   <span class="font13">care </span>
   <span class="font13">conditionally </span>
   <span class="font13">episode </span>
   <span class="font13">study </span>
   <span class="font13">therapy </span>
   <span class="font13">CVS, </span>
   <span class="font13">evidence </span>
   <span class="font13">using </span>
   <span class="font13">dose </span>
   <span class="font13">effective </span>
   <span class="font13">medication </span>
   <span class="font13">studies </span>
   <span class="font12">abortive </span>
   <span class="font12">low‐quality </span>
   <span class="font12">medications </span>
   <span class="font12">topiramate </span>
   <span class="font12">Clin </span>
   <span class="font12">Syndrome </span>
   <span class="font12">Vomiting </span>
   <span class="font12">adult </span>
   <span class="font12">children </span>
   <span class="font12">moderate‐to‐severe </span>
   <span class="font12">onset </span>
   <span class="font12">receive </span>
   <span class="font12">review </span>
   <span class="font12">guideline </span>
   <span class="font12">include </span>
   <span class="font12">recommendations </span>
   <span class="font12">response </span>
   <span class="font12">syndrome: </span>
   <span class="font12">[], </span>
   <span class="font12">antagonists </span>
   <span class="font12">case </span>
   <span class="font12">daily </span>
   <span class="font12">emergency </span>
   <span class="font12">oral </span>
   <span class="font12">receptor </span>
   <span class="font12">severe </span>
   <span class="font12">vomiting. </span>
   <span class="font12">American </span>
   <span class="font12">Neurogastroenterol </span>
   <span class="font12">Recommendation </span>
   <span class="font12">Rome </span>
   <span class="font12">Vote: </span>
   <span class="font12">ondansetron </span>
   <span class="font12">reported </span>
   <span class="font11">Clinical </span>
   <span class="font11">GRADE </span>
   <span class="font11">Society </span>
   <span class="font11">abort </span>
   <span class="font11">agreement </span>
   <span class="font11">cannabis </span>
   <span class="font11">data </span>
   <span class="font11">diagnostic </span>
   <span class="font11">disorders </span>
   <span class="font11">experience </span>
   <span class="font11">levetiracetam </span>
   <span class="font11">likely </span>
   <span class="font11">nasal </span>
   <span class="font11">number </span>
   <span class="font11">pain </span>
   <span class="font11">patients. </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">reduction </span>
   <span class="font11">serotonin </span>
   <span class="font11">tricyclic </span>
   <span class="font11">Association </span>
   <span class="font11">Autonomic </span>
   <span class="font11">Health </span>
   <span class="font11">Med </span>
   <span class="font11">Motil. </span>
   <span class="font11">Participation </span>
   <span class="font11">Table </span>
   <span class="font11">abdominal </span>
   <span class="font11">alternate </span>
   <span class="font11">and/or </span>
   <span class="font11">chronic </span>
   <span class="font11">complete </span>
   <span class="font11">conditions </span>
   <span class="font11">criteria </span>
   <span class="font11">department </span>
   <span class="font11">development, </span>
   <span class="font11">drug </span>
   <span class="font11">history </span>
   <span class="font11">literature </span>
   <span class="font11">px; </span>
   <span class="font11">research </span>
   <span class="font11">retrospective </span>
   <span class="font11">supplements </span>
   <span class="font11">syndrome. </span>
   <span class="font11">systematic </span>
   <span class="font11">{font-family </span>
   <span class="font11">(%) </span>
   <span class="font11">Boles </span>
   <span class="font11">Chelimsky </span>
   <span class="font11">Co‐Q </span>
   <span class="font11">Division </span>
   <span class="font11">Gastroenterol </span>
   <span class="font11">Gastroenterology </span>
   <span class="font11">Mitochondrial </span>
   <span class="font11">Neurol. </span>
   <span class="font11">Venkatesan </span>
   <span class="font11">adolescents </span>
   <span class="font11">agents </span>
   <span class="font11">appropriate </span>
   <span class="font11">drugs </span>
   <span class="font11">emptying </span>
   <span class="font11">episodes. </span>
   <span class="font11">evidence) </span>
   <span class="font11">evidence. </span>
   <span class="font11">font-size </span>
   <span class="font11">gastric </span>
   <span class="font11">given </span>
   <span class="font11">headache </span>
   <span class="font11">inter‐episodic </span>
   <span class="font11">mitochondrial </span>
   <span class="font11">outcomes </span>
   <span class="font11">overall </span>
   <span class="font11">randomized </span>
   <span class="font11">recommendation, </span>
   <span class="font11">recommended </span>
   <span class="font11">refractory </span>
   <span class="font11">riboflavin </span>
   <span class="font11">study. </span>
   <span class="font11">substance </span>
   <span class="font11">suggest </span>
   <span class="font11">target </span>
   <span class="font11">treated </span>
   <span class="font11">trials </span>
   <span class="font11">zonisamide </span>
   <span class="font11">(very </span>
   <span class="font11">Adams </span>
   <span class="font11">Conditional </span>
   <span class="font11">Gastroenterol. </span>
   <span class="font11">Grade: </span>
   <span class="font11">However, </span>
   <span class="font11">Medical </span>
   <span class="font11">Motility </span>
   <span class="font11">Neurogastroenterology </span>
   <span class="font11">Pediatric </span>
   <span class="font11">Significant </span>
   <span class="font11">TCAs </span>
   <span class="font11">Ther. </span>
   <span class="font11">Treatment </span>
   <span class="font11">amitriptyline </span>
   <span class="font11">amitriptyline, </span>
   <span class="font11">anxiety, </span>
   <span class="font11">associated </span>
   <span class="font11">autonomic </span>
   <span class="font11">best </span>
   <span class="font11">chemotherapy‐induced </span>
   <span class="font11">considered </span>
   <span class="font11">diagnosis, </span>
   <span class="font11">double; </span>
   <span class="font11">duration </span>
   <span class="font11">expert </span>
   <span class="font11">function </span>
   <span class="font11">functional </span>
   <span class="font11">headache, </span>
   <span class="font11">high </span>
   <span class="font11">improve </span>
   <span class="font11">included </span>
   <span class="font11">including </span>
   <span class="font11">increased </span>
   <span class="font11">individual </span>
   <span class="font11">lack </span>
   <span class="font11">liver </span>
   <span class="font11">members </span>
   <span class="font11">patients, </span>
   <span class="font11">phase </span>
   <span class="font11">present </span>
   <span class="font11">protocol </span>
   <span class="font11">provided </span>
   <span class="font11">psychiatric </span>
   <span class="font11">recommends </span>
   <span class="font11">renal </span>
   <span class="font11">sedation </span>
   <span class="font11">serum </span>
   <span class="font11">severity </span>
   <span class="font11">shown </span>
   <span class="font11">standard </span>
   <span class="font11">therapeutic </span>
   <span class="font11">trial </span>
   <span class="font11">triptans </span>
   <span class="font11">twice </span>
   <span class="font11">‐HT </span>
   <span class="font11">&amp;gt; </span>
   <span class="font11">(C) </span>
   <span class="font11">BMC </span>
   <span class="font11">Based </span>
   <span class="font11">Figure </span>
   <span class="font11">Guidelines </span>
   <span class="font11">Hejazi </span>
   <span class="font11">John </span>
   <span class="font11">Pharmacol </span>
   <span class="font11">Retainer </span>
   <span class="font11">Sumatriptan </span>
   <span class="font11">University </span>
   <span class="font11">Wiley </span>
   <span class="font11">Wisconsin </span>
   <span class="font11">administration </span>
   <span class="font11">anxiety </span>
   <span class="font11">biofeedback </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">comorbid </span>
   <span class="font11">defined </span>
   <span class="font11">described </span>
   <span class="font11">disorder </span>
   <span class="font11">disorders, </span>
   <span class="font11">doses </span>
   <span class="font11">family </span>
   <span class="font11">first‐line </span>
   <span class="font11">health </span>
   <span class="font11">help </span>
   <span class="font11">influence </span>
   <span class="font11">like </span>
   <span class="font11">limited </span>
   <span class="font11">mean </span>
   <span class="font11">migraine. </span>
   <span class="font11">multiple </span>
   <span class="font11">open‐label </span>
   <span class="font11">orthostatic </span>
   <span class="font11">partial </span>
   <span class="font11">pediatric </span>
   <span class="font11">prodrome </span>
   <span class="font11">reduce </span>
   <span class="font11">report </span>
   <span class="font11">screening </span>
   <span class="font11">sleep </span>
   <span class="font11">solid; </span>
   <span class="font11">support, </span>
   <span class="font11">symptoms. </span>
   <span class="font11">therapy. </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">(%), </span>
   <span class="font10">(CVS) </span>
   <span class="font10">Amitriptyline </span>
   <span class="font10">CYPD </span>
   <span class="font10">Cannabinoid </span>
   <span class="font10">Center </span>
   <span class="font10">Consensus </span>
   <span class="font10">Department </span>
   <span class="font10">Epilepsia. </span>
   <span class="font10">Eur </span>
   <span class="font10">Given </span>
   <span class="font10">Headache. </span>
   <span class="font10">Ltd, </span>
   <span class="font10">McCallum </span>
   <span class="font10">Migraine </span>
   <span class="font10">Patients </span>
   <span class="font10">Pediatr </span>
   <span class="font10">QTc </span>
   <span class="font10">Recommendations </span>
   <span class="font10">Sons, </span>
   <span class="font10">achieved </span>
   <span class="font10">additional </span>
   <span class="font10">adults: </span>
   <span class="font10">algorithm </span>
   <span class="font10">antidepressant </span>
   <span class="font10">approach </span>
   <span class="font10">article </span>
   <span class="font10">attacks, </span>
   <span class="font10">blood </span>
   <span class="font10">bold </span>
   <span class="font10">cases </span>
   <span class="font10">cognitive </span>
   <span class="font10">combination </span>
   <span class="font10">comparison </span>
   <span class="font10">complementary </span>
   <span class="font10">condition </span>
   <span class="font10">consensus </span>
   <span class="font10">courier; </span>
   <span class="font10">criteria, </span>
   <span class="font10">days </span>
   <span class="font10">depression, </span>
   <span class="font10">developing </span>
   <span class="font10">development </span>
   <span class="font10">different </span>
   <span class="font10">discussed </span>
   <span class="font10">disease </span>
   <span class="font10">duration, </span>
   <span class="font10">dysfunction </span>
   <span class="font10">dysfunction, </span>
   <span class="font10">early </span>
   <span class="font10">em; </span>
   <span class="font10">exclude </span>
   <span class="font10">features </span>
   <span class="font10">following </span>
   <span class="font10">fosaprepitant </span>
   <span class="font10">frequency </span>
   <span class="font10">guidelines </span>
   <span class="font10">healthcare </span>
   <span class="font10">imaging </span>
   <span class="font10">improves </span>
   <span class="font10">indicated </span>
   <span class="font10">long‐term </span>
   <span class="font10">majority </span>
   <span class="font10">measured </span>
   <span class="font10">medication. </span>
   <span class="font10">months </span>
   <span class="font10">months, </span>
   <span class="font10">particularly </span>
   <span class="font10">pattern </span>
   <span class="font10">patterns </span>
   <span class="font10">performed </span>
   <span class="font10">preventing </span>
   <span class="font10">pt;} </span>
   <span class="font10">referral </span>
   <span class="font10">related </span>
   <span class="font10">risk </span>
   <span class="font10">separate </span>
   <span class="font10">series </span>
   <span class="font10">significant </span>
   <span class="font10">significantly </span>
   <span class="font10">single </span>
   <span class="font10">sleep, </span>
   <span class="font10">strongly </span>
   <span class="font10">tests </span>
   <span class="font10">treatment. </span>
   <span class="font10">typical </span>
   <span class="font10">underlying </span>
   <span class="font10">use. </span>
   <span class="font10">useful </span>
  </p>
 </body>
</html>
